Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4226695 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY4226695 Part A | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered subcutaneously (SC) |
| LY4226695 Part B | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered SC |
| LY4226695 Part C | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered SC |
| LY4226695 Part D | EXPERIMENTAL | Participants will receive LY4226695 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4226695 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a screening body mass index (BMI) in the range of 18.5 to 35 kilograms per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening. * Individuals assigned male at birth must agree to adhere to contraception restrict...
LY4226695 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single recruiting study in healthy participants. No therapeutic indication has been disclosed for the compound.
LY4226695 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants.
LY4226695 is in Phase 1 clinical development. It has one active, recruiting trial and no completed trials. The compound is investigational and has not been approved by the FDA for any indication.
LY4226695 is being evaluated in a single Phase 1 trial, NCT07767487, titled A Study of LY4226695 in Healthy Participants. The study is recruiting, is randomized, double-blind, and controlled, and plans to enroll 148 healthy volunteers in the United States and Singapore.
The NCT07767487 trial enrolls healthy volunteers of all sexes who are at least 22 years old. It is a randomized, double-blind, controlled Phase 1 study with a planned enrollment of 148 participants across sites in the United States and Singapore.